Table 4. Number of Research Projects Included Under Each Cross-Cutting Theme and WHO Priority Area (known funding amounts indicated in brackets).
WHO Priority Area | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Cross-Cutting Area | Number of
Projects |
Virus:
natural history... |
Animal and
environmental research... |
Epidemiological
studies |
Clinical
characterization and management |
Infection
prevention and control... |
Candidate
therapeutics R&D |
Candidate
vaccines R&D |
Ethics
considerations for research |
Social
sciences in the outbreak response |
N/A |
Innovation ($160.7m) |
![]() |
91 | 0 | 33 | 241 | 355 | 28 | 16 | 3 | 279 | 202 |
Repurposed ($386.5m) |
![]() |
172 | 6 | 77 | 202 | 59 | 130 | 36 | 6 | 276 | 52 |
Modelling ($163.5m) |
![]() |
119 | 8 | 355 | 71 | 96 | 47 | 26 | 7 | 128 | 13 |
Indirect Health Impacts ($90.1m) |
![]() |
5 | 0 | 29 | 116 | 20 | 1 | 0 | 1 | 436 | 19 |
Cohorts ($313.9m) |
![]() |
79 | 0 | 84 | 131 | 16 | 17 | 9 | 2 | 110 | 11 |
Long COVID ($208.3m) |
![]() |
19 | 1 | 25 | 114 | 2 | 7 | 2 | 0 | 21 | 0 |
Gender ($26.0m) |
![]() |
1 | 0 | 3 | 2 | 4 | 0 | 1 | 3 | 131 | 1 |
Capacity Strengthening ($196.8m) |
![]() |
32 | 1 | 19 | 20 | 11 | 13 | 5 | 5 | 56 | 7 |
Pandemic Preparedness ($103.2m) |
![]() |
14 | 2 | 20 | 15 | 15 | 6 | 5 | 4 | 55 | 5 |
Implementation ($347.5m) |
![]() |
13 | 0 | 5 | 8 | 8 | 8 | 2 | 1 | 19 | 37 |
New Variant ($11.3m) |
![]() |
13 | 1 | 6 | 2 | 0 | 0 | 6 | 0 | 0 | 0 |
Notes:
i. Research projects may be assigned with multiple cross-cutting themes and WHO priority areas
ii. Highlighted cells indicate the WHO Priority Area with the greatest number of projects for each cross-cutting theme (excluding projects that were not assigned a priority area, marked N/A).
iii. Funding figures available for 59.2% of projects included in the latest version of the tracker database as not all funders provided financial information.
iv. Definitions of cross-cutting themes-
◦ Capacity strengthening: Projects which involve a capacity strengthening component. Capacity strengthening at all levels- individual, institutional and national is included.
◦ Cohorts: Projects carried out in newly established cohorts or pivoted existing cohorts for COVID-19 research.
◦ Gender: Projects which incorporate a gendered lens in description of methods/ objectives and project outputs.
◦ Implementation: Grants for facilitating research administration.
◦ Indirect Health Impacts: Projects focusing on indirect health impacts of COVID-19, for example related to disruptions in healthcare services, neonatal, maternal and child health, non-communicable diseases, chronic disease conditions and mental health.
◦ Innovation: Projects involving novel inventions and interventions.
◦ Long COVID: Projects involving the long-term morbidity and enduring symptoms of COVID-19 beyond the initial infection.
◦ Modelling: Projects involving any form of modelling in the methodology.
◦ New Variants : Projects involving new variants of the coronavirus that cause COVID-19.
◦ Pandemic Preparedness: Projects with preparedness for future pandemics as an objective.
◦ Repurposed projects: Pre-COVID research grants (usually for MERS, SARS and other pathogens) where additional funding has been awarded for tailoring to COVID-19 research.